{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T23:29:18Z","timestamp":1648769358267},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00105-021-04766-9","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:47:45Z","timestamp":1613738865000},"page":"909-912","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Niedrig dosierte Fumars\u00e4ureester-Langzeittherapie bei behandlungsresistenter kutaner Sarkoidose"],"prefix":"10.1007","volume":"72","author":[{"given":"Christos C.","family":"Zouboulis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"4766_CR1","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/j.1365-2133.2005.06585.x","volume":"152","author":"K Breuer","year":"2005","unstructured":"Breuer\u00a0K, Gutzmer\u00a0R, V\u00f6lker\u00a0B, Kapp\u00a0A, Werfel\u00a0T (2005) Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol 152:1290\u20131295","journal-title":"Br J Dermatol"},{"key":"4766_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40257-019-00428-8","volume":"20","author":"D Dai","year":"2019","unstructured":"Dai\u00a0D, Shih\u00a0S, Ansari\u00a0A, Kwak\u00a0Y, Sami\u00a0N (2019) Biologic therapy in the treatment of cutaneous sarcoidosis: a literature review. Am J Clin Dermatol 20:409\u2013422","journal-title":"Am J Clin Dermatol"},{"key":"4766_CR3","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","volume":"264","author":"RJ Gieselbach","year":"2017","unstructured":"Gieselbach\u00a0RJ, Muller-Hansma\u00a0AH, Wijburg\u00a0MT et al (2017) Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a\u00a0review of 19\u00a0cases. J\u00a0Neurol 264:1155\u20131164","journal-title":"J Neurol"},{"key":"4766_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.clim.2011.02.017","volume":"142","author":"R Gold","year":"2012","unstructured":"Gold\u00a0R, Linker\u00a0RA, Stangel\u00a0M (2012) Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 142:44\u201348","journal-title":"Clin Immunol"},{"key":"4766_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00105-004-0728-1","volume":"55","author":"R Gutzmer","year":"2004","unstructured":"Gutzmer\u00a0R, Kapp\u00a0A, Werfel\u00a0T (2004) Erfolgreiche Therapie einer Haut- und Lungensarkoidose mit Fumars\u00e4ureestern. Hautarzt 55:553\u2013557","journal-title":"Hautarzt"},{"key":"4766_CR6","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1111\/exd.12065","volume":"22","author":"P Hoyer","year":"2013","unstructured":"Hoyer\u00a0P, Scharf\u00a0S, Danneberg\u00a0R, Kroll\u00a0H, Zouboulis\u00a0CC, Lippert\u00a0U (2013) Mechanisms of fumaric acid ester action on granuloma formation. Exp Dermatol 22:e36","journal-title":"Exp Dermatol"},{"key":"4766_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.mcna.2018.12.011","volume":"103","author":"O Lianos","year":"2019","unstructured":"Lianos\u00a0O, Hamzeh\u00a0N (2019) Sarcoidosis. Med Clin North Am 103:527\u2013534","journal-title":"Med Clin North Am"},{"key":"4766_CR8","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3745","author":"T Miura","year":"2020","unstructured":"Miura\u00a0T, Kikuchi\u00a0N, Yamamoto\u00a0T (2020) Cutaneous sarcoidosis in 95 Japanese patients: a\u00a0single institutional study. Eur J Dermatol. https:\/\/doi.org\/10.1684\/ejd.2020.3745","journal-title":"Eur J Dermatol"},{"key":"4766_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-5945-2-15","volume":"2","author":"U Nowack","year":"2002","unstructured":"Nowack\u00a0U, Gambichler\u00a0T, Hanefeld\u00a0C, Kastner\u00a0U, Altmeyer\u00a0P (2002) Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2:15","journal-title":"BMC Dermatol"},{"key":"4766_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/ced.13623","volume":"43","author":"S Rolls","year":"2018","unstructured":"Rolls\u00a0S, Porter\u00a0W (2018) Oral Fumaderm\u00ae to treat cutaneous sarcoidosis. Clin Exp Dermatol 43:611\u2013613","journal-title":"Clin Exp Dermatol"},{"key":"4766_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/sj.jid.5700996","volume":"128","author":"SA Rubant","year":"2008","unstructured":"Rubant\u00a0SA, Ludwig\u00a0RJ, Diehl\u00a0S, Hardt\u00a0K, Kaufmann\u00a0R, Pfeilschifter\u00a0JM, Boehncke\u00a0WH (2008) Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J\u00a0Invest Dermatol 128:326\u2013331","journal-title":"J Invest Dermatol"},{"key":"4766_CR12","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMc1300283","volume":"368","author":"MT Sweetser","year":"2013","unstructured":"Sweetser\u00a0MT, Dawson\u00a0KT, Bozic\u00a0C (2013) Manufacturer\u2019s response to case reports of PML. N\u00a0Engl J Med 368:1659\u20131661","journal-title":"N Engl J Med"},{"key":"4766_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1742-2094-7-30","volume":"7","author":"H Wilms","year":"2010","unstructured":"Wilms\u00a0H, Sievers\u00a0J, Rickert\u00a0U, Rostami-Yazdi\u00a0M, Mrowietz\u00a0U, Lucius\u00a0R (2010) Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL\u20116 in an in-vitro model of brain inflammation. J\u00a0Neuroinflammation 7:30","journal-title":"J Neuroinflammation"},{"key":"4766_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s00105-012-2386-z","volume":"63","author":"A Wolter","year":"2012","unstructured":"Wolter\u00a0A, M\u00fcller\u00a0M, V\u00f6lker\u00a0B, Gehring\u00a0M, Caldarone\u00a0F, Kapp\u00a0A, Werfel\u00a0T, Raap\u00a0U (2012) Kutane und pulmonale Sarkoidose \u2013 Erfolgreiche Therapie mit Fumars\u00e4ureestern. Hautarzt 63:808\u2013812","journal-title":"Hautarzt"},{"key":"4766_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1523-1747.2001.01159.x","volume":"116","author":"K Zhu","year":"2001","unstructured":"Zhu\u00a0K, Mrowietz\u00a0U (2001) Inhibition of dendritic cell differentiation by fumaric acid esters. J\u00a0Invest Dermatol 116:203\u2013208","journal-title":"J Invest Dermatol"},{"key":"4766_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000358428","volume":"228","author":"CC Zouboulis","year":"2014","unstructured":"Zouboulis\u00a0CC, Lippert\u00a0U, Karagiannidis\u00a0I (2014) Multi-organ sarcoidosis treatment with fumaric acid esters: a\u00a0case report and review of the literature. Dermatology 228:202\u2013206","journal-title":"Dermatology"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04766-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04766-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T15:44:41Z","timestamp":1632411881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04766-9"}},"subtitle":["Bericht \u00fcber 2\u00a0F\u00e4lle"],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4766"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04766-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"18 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.C.\u00a0Zouboulis hat Honorare von Almirall, dem derzeitigen Hersteller von Dimethylfumarat, erhalten, die nicht mit diesem Manuskript, der klinischen Indikation oder dem verabreichten Medikament in Verbindung stehen. Seine Abteilung erhielt von Biogen-Idec, dem ehemaligen Hersteller von Fumaderm\u00ae, eine vom Autor initiierte, kompetitive Forschungsf\u00f6rderung f\u00fcr In-vitro-Studien zu den Auswirkungen von Fumars\u00e4ureestern in vitro.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten individuellen Heilversuche gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}